Testing FIRST in Youth Outpatient Psychotherapy
Launched by HARVARD UNIVERSITY · Jan 23, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called FIRST, which stands for "Focused Interventions for Stressful Transitions," to see how it helps young people with mental health issues like anxiety, depression, trauma, and behavior problems. FIRST is designed to work on common emotional challenges and is being compared to regular therapy to determine which is more effective in improving mental health and managing negative emotions.
The trial is looking for children and teenagers aged 7 to 15 who show signs of anxiety, depression, or other behavioral issues. To participate, they need to speak English and have scores that indicate they are experiencing significant mental health challenges. However, those with serious issues like current suicide risk, certain eating disorders, or other specific diagnoses won’t be eligible. Participants will receive either the FIRST treatment or usual care and will be monitored to see how their mental health improves over time. This is a great opportunity for eligible youths to receive support while contributing to important research in mental health treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ages 7.0-15.9 years
- • at least one clinically-relevant CBCL subscale score indicating borderline/clinical-range anxiety, depression, conduct problems, or post-traumatic stress
- • English fluency indicated by taking all school classes in English
- Exclusion Criteria:
- • current suicide risk, operationalized as active suicidal ideation or a history of suicide attempt or inpatient hospitalization for suicide risk within the last 3 months
- • presence of an eating disorder, schizophrenia spectrum disorder, autism spectrum disorder, or intellectual disability requiring special class placement in school
- • referral for ADHD if specifically and exclusively to address inattentiveness and/or hyperactivity-impulsivity
About Harvard University
Harvard University, a prestigious Ivy League institution, is a leading sponsor of clinical trials, dedicated to advancing medical research and improving patient outcomes. With a strong emphasis on innovation and interdisciplinary collaboration, Harvard leverages its world-class faculty, cutting-edge facilities, and extensive resources to conduct rigorous clinical studies across various fields, including medicine, public health, and biomedical sciences. The university is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the safety and well-being of participants while contributing valuable insights to the global healthcare community. Through its clinical research initiatives, Harvard aims to translate scientific discoveries into effective treatments and preventive strategies that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, Massachusetts, United States
Austin, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials